Chrysin (Flavone · Aromatase Inhibitor · Anxiolytic)

Compound	Chrysin (5,7-Dihydroxyflavone; Galangin 3-deoxy; Propolis flavone)
Chemical class	Polyphenol — Flavone (simplest dihydroxyflavone; no B-ring substituents)
CAS	480-40-0
Primary source	Propolis (bee resin), Passiflora caerulea (passion flower), Oroxylum indicum, Pinus spp.
Key applications	Aromatase (CYP19A1) inhibition; anxiolytic (GABA-A); anti-inflammatory; testosterone support
Claim strength	Moderate
Typical form	Chrysin Powder (direct isolate); Propolis Extract; Passion Flower Extract Powder
Buy from Herbuno	Chrysin Powder → Passion Flower Extract Powder →

Name origin: Chrysin takes its name from the Greek chrysos (gold) — reflecting the golden-yellow colour of propolis, its primary commercial source. It is the simplest naturally occurring dihydroxyflavone: apigenin without the 4′-hydroxyl on the B-ring, giving chrysin a completely unsubstituted phenyl B-ring. Traditional use: Propolis has been used continuously for at least 2,000 years in folk medicine — documented in Egyptian mummification, Hippocratic medicine for wound treatment, and Aristotelian natural philosophy. Its antimicrobial, wound-healing, and anti-inflammatory properties are extensively recorded across cultures. Passionflower (Passiflora spp.) has traditional use in European and North American herbal medicine for anxiety, insomnia, and nervous tension, with chrysin identified as one of the GABAergic constituents contributing to the anxiolytic activity. Research trajectory: Chrysin gained significant attention in the 1980s-90s as a natural aromatase inhibitor following in vitro studies showing CYP19A1 inhibition. This drove its popularity in testosterone-support supplements, particularly in bodybuilding. Subsequent research clarified that chrysin's poor oral bioavailability (<1% without absorption enhancers) limits its in vivo aromatase-inhibiting activity — necessitating co-formulation with piperine or phospholipid complexes. Commercial source: Chrysin Powder (direct high-purity isolate) and Passion Flower Extract Powder are available from Herbuno — the isolated powder being the most practical form for bioavailability-enhanced formulations.

---

Evidence for Chrysin Applications

Aromatase inhibition (CYP19A1): Chrysin is a competitive inhibitor of aromatase (CYP19A1) — the enzyme converting androstenedione and testosterone to oestrogens. In cell-free and cell-based assays, chrysin's IC₅₀ for aromatase is 2–5 μM, making it one of the more potent flavone aromatase inhibitors. In vivo, however, the aromatase-inhibiting effect is substantially attenuated by poor oral bioavailability. A human study (Hamden et al.) demonstrated improved testosterone levels in men with metabolic syndrome taking chrysin combined with piperine (20 mg piperine raised plasma chrysin ~30-fold), supporting the bioavailability-dependent in vivo hypothesis. Claim strength: Moderate (with bioavailability enhancer); Emerging (without).

Anxiolytic (GABA-A positive modulation): Chrysin binds the benzodiazepine binding site of GABA-A receptors with Kᵢ ~3 μM in radioligand binding assays — a direct anxiolytic mechanism shared with diazepam but with lower affinity. In rodent elevated plus maze and Vogel conflict models, chrysin at 1–3 mg/kg produces significant anxiolytic effects without sedation or muscle relaxation at these doses. The anxiolytic activity of passionflower extract is partly attributed to chrysin alongside vitexin and isovitexin. Claim strength: Moderate.

Anti-inflammatory: COX-2 and 5-LOX inhibition, NF-κB pathway suppression, and TNF-α reduction are documented for chrysin at 10–50 μM in macrophage and mast cell models. Inhibition of LPS-induced iNOS expression and NO production contributes to anti-inflammatory activity in neuroinflammation models. Claim strength: Moderate.

Antioxidant and neuroprotective: Chrysin activates Nrf2/HO-1 signalling and scavenges DPPH/ABTS radicals, with protective effects in rotenone-induced Parkinson's, Aβ-induced Alzheimer's, and H₂O₂-induced oxidative stress neuronal models. Claim strength: Moderate.

---

Dosage & Formulator Specification

Chrysin has extremely poor oral bioavailability in standard supplement formulations — plasma levels after 400–3000 mg oral chrysin are at or near the limit of detection without absorption enhancement. This is the most critical specification decision for formulators. Two strategies address this: (1) co-formulation with piperine (5–20 mg per serving) which inhibits intestinal and hepatic glucuronidation and raises plasma chrysin ~20–30-fold; (2) phospholipid complexation (Phytosome® technology) or self-emulsifying delivery systems which improve dissolution and membrane partitioning.

For testosterone-support and aromatase-inhibiting applications, chrysin 500–1000 mg per serving with piperine 5–20 mg is the commercially most viable specification with the best evidence base. For anxiolytic applications, passionflower extract (providing chrysin alongside vitexin and isovitexin at physiologically relevant ratios) at 300–500 mg is the more established clinical delivery vehicle.

Chrysin is highly lipophilic (logP ~3.2) and requires lipid-based or emulsified delivery for optimal bioavailability. Compatible with testosterone-supporting ingredients (zinc, ashwagandha, boron, fenugreek) in male health formulas. Anti-inflammatory stacks combining chrysin with quercetin, luteolin, or baicalin leverage overlapping but additive mechanistic coverage.

No clinically significant drug interactions are documented for chrysin at supplement doses. Given the GABA-A modulation, caution with high-dose chrysin combined with benzodiazepines, alcohol, or other CNS depressants is theoretically warranted, though supplement-level exposures without bioavailability enhancement are unlikely to reach pharmacologically significant CNS concentrations.

---

Frequently Asked Questions — Chrysin

Is chrysin effective for raising testosterone without an absorption enhancer?
No — not meaningfully. Standard oral chrysin has bioavailability <1% due to extensive intestinal and first-pass glucuronidation. Plasma concentrations after 3 g oral chrysin without piperine are below the range required for meaningful CYP19A1 inhibition in tissue. With piperine (20 mg), plasma chrysin increases ~20–30-fold, reaching concentrations where in vivo aromatase inhibition is biologically plausible. Formulations without bioavailability enhancement are unlikely to produce testosterone-supporting effects regardless of dose.

How does chrysin compare to pharmaceutical aromatase inhibitors like anastrozole?
Anastrozole (Arimidex) is a non-steroidal triazole aromatase inhibitor — the gold-standard pharmaceutical for oestrogen-receptor-positive breast cancer and off-label use in hypogonadal men. Its IC₅₀ for aromatase is ~15 pM — approximately 100,000-fold more potent than chrysin's 2–5 μM. Chrysin at achievable supplemental concentrations is a mild, partial, reversible aromatase modulator appropriate for nutritional context; anastrozole and similar pharmaceuticals operate in an entirely different potency category.

Is chrysin the same as propolis flavone or is propolis a better source?
Chrysin is one of the primary flavones of temperate-region propolis (particularly European poplar propolis), alongside galangin, pinocembrin, and caffeic acid phenethyl ester (CAPE). Propolis extract provides chrysin within its full flavonoid matrix, which may confer broader bioactivity than isolated chrysin. However, for standardised chrysin delivery with controlled dosing and bioavailability enhancement, isolated chrysin powder (as from Herbuno) is more practical than variable propolis preparations.

What is the anxiolytic mechanism of chrysin in passionflower?
Chrysin binds the benzodiazepine site on GABA-A receptors (alpha subunit interface), acting as a partial positive allosteric modulator — enhancing GABA-induced chloride conductance and reducing neuronal excitability. In passionflower, chrysin's GABAergic activity complements vitexin (5-HT1A partial agonism) and isovitexin (GABA-A modulation), creating a multi-mechanistic anxiolytic profile that explains passionflower's superior clinical evidence versus single-compound anxiolytics from the same plant.

Related compounds: Apigenin, Acacetin, Diosmetin, Scutellarein

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery